Steroidal glycolipid, L-644,257, is a potent enhancer of nonspecific host resistance.
A steroidal glycolipid that enhances the nonspecific cellular response to opportunistic infection in an immunocompromised host has been discovered. A dose dependent response with 6-(5-cholesten-3 beta-yloxy)hexyl 1-thio-beta-D-mannopyranoside, L-644,257, was observed against several infective agents including bacterial, fungal, and viral pathogens in cyclophosphamide-treated mice. A mechanism for this protective action is proposed.
Hagmann
W K
WK
Department of Medicinal Chemical Research, Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065.
Ponpipom
M M
MM
Jackson
J J
JJ
Wood
D D
DD
Boltz
R C
RC
Zweerink
H J
HJ
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D002177:Candidiasis / Q000276:immunology; D002784:Cholesterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D007113:Immunity, Innate / Q000187:drug effects*; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D011552:Pseudomonas Infections / Q000276:immunology; D013203:Staphylococcal Infections / Q000276:immunology; D013997:Time Factors
D000276:Adjuvants, Immunologic; C030513:L 644257; D002784:Cholesterol